MORE►
precision medicine
David Spetzler, president of Caris Life Sciences [Image: Caris Life Sciences]
Caris Life Sciences Partners with Moderna To Advance mRNA-Based Cancer Drugs
by Lance Murray | Oct 24, 2023
Irving-based Caris said that via this multiyear agreement, Moderna will leverage Caris’ extensive library of de-identified, multimodal data solutions derived from whole exome sequencing, whole transcriptome sequencing, and protein analyses—along with claims data to improve development strategies for Moderna’s oncology pipeline.
by Alex Edwards |
May 12, 2021
Now valued at more than $7.8 billion, Caris specializes in AI-powered genetic sequencing for personalized cancer treatments. The massive capital raise follows a $310 million round in October and boosts the 13-year-old company's total funding to about $1.3 billion.
MORE►
by Alex Edwards |
Oct 27, 2020
The growth capital will allow Caris to advance its position as a leading tumor profiling company that aims to reinvent cancer care.
MORE►
by Lance Murray |
Mar 2, 2018
The new center, on the campus of UT Arlington, will be available to academic and corporate researchers. Official said it could help elevate the region as a leader in precision medicine.
MORE►
